Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Journal Article

  

Authors:	Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
Article Title:	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
Abstract:	Background: Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial of sunitinib versus interferon-α (IFN-α) as first-line metastatic renal cell carcinoma (RCC) therapy. Design: A multivariate Cox regression model analyzed baseline variables for prognostic significance. Each variable was investigated univariately and then multivariately using a stepwise algorithm. Results: Each treatment arm comprised 375 patients. For sunitinib, multivariate analysis of PFS identified five independent predictors, including serum lactate dehydrogenase (LDH) level, presence of ≥2 metastatic sites, no prior nephrectomy, Eastern Cooperative Oncology Group (ECOG) performance status, and baseline platelet count, while multivariate analysis of OS identified serum LDH level, corrected serum calcium level, time from diagnosis to treatment, hemoglobin level, ECOG performance status, and presence of bone metastasis as predictors. For IFN-α, LDH level and presence of ≥2 metastatic sites were common predictors of PFS to those for sunitinib, as were all predictors of OS except ECOG status. Conclusions: This analysis identified prognostic factors for PFS and OS with sunitinib as first-line metastatic RCC therapy and confirmed that the Memorial Sloan-Kettering Cancer Center model is applicable in the era of targeted therapy. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Keywords:	aged; survival analysis; major clinical study; overall survival; cancer localization; sunitinib; antineoplastic agents; bone metastasis; alpha interferon; progression free survival; randomized controlled trial; calcium; hemoglobin; calcium blood level; hemoglobin blood level; prediction; renal cell carcinoma; kidney carcinoma; kidney neoplasms; nephrectomy; carcinoma, renal cell; disease progression; multicenter study; prognostic factors; neoplasm metastasis; thrombocyte count; lactate dehydrogenase; metastasis potential; phase 3 clinical trial; indoles; pyrroles; lactate dehydrogenase blood level; performance measurement system; memorial sloan-kettering cancer center risk groups; interferon-?
Journal Title:	Annals of Oncology
Volume:	22
Issue:	2
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2011-02-01
Start Page:	295
End Page:	300
Language:	English
DOI:	10.1093/annonc/mdq342
PROVIDER:	scopus
PUBMED:	20657034
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-79251574372&partnerID=40&md5=aa7afaadf96a6cbda2322113e0f59e0a
Notes:	--- - "Export Date: 4 March 2011" - "CODEN: ANONE" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/3460